文献速递血液净化与透析肾血管病与高血压

三甲胺N-氧化物与维持性血液透析ESKD患者的心血管结局

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-01-21

本研究基于EVOLVE试验的1243例接受维持性血液透析的ESKD患者,测量基线血清TMAO浓度并分析其与心血管结局的关联。结果显示约80%患者TMAO≥56 µM,最高达1103.1 µM,但未发现TMAO与主要复合心血管结局、全因死亡率等存在关联。

要点

  • 在维持性血液透析的ESKD患者中,基线血清TMAO水平与心血管结局无显著关联。
  • 约80%的参与者TMAO浓度≥56 µM,提示该人群TMAO水平普遍升高。
  • 未证实既往研究中TMAO与种族的交互作用。

核心结论

  • 在合并中重度继发性甲状旁腺功能亢进的维持性血液透析患者中,未发现TMAO与不良临床结局相关的证据。

研究设计与样本

  • 对EVOLVE试验中1243例参与者的基线血清TMAO浓度进行测量,并开展事后分析评估其与心血管结局的关联。

主要发现

  • 血清TMAO分布广泛,约80%参与者TMAO浓度≥56 µM,最高达1103.1 µM。
  • TMAO与主要复合结局(心血管死亡、心肌梗死、外周血管事件、卒中、不稳定心绞痛住院)无关联。
  • 在未调整和调整分析中,TMAO与全因死亡率、复合结局各独立组分及原始EVOLVE主要结局均无关联。
  • 白人参与者TMAO浓度较高,但亚组分析未证实既往研究中TMAO与种族的交互作用。

临床怎么用

  • 对于维持性血液透析的ESKD患者,血清TMAO水平不宜作为心血管风险分层的常规指标。

局限性

  • 本研究为事后分析,结果需前瞻性研究验证。
  • 研究人群限于合并中重度继发性甲状旁腺功能亢进的血液透析患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Trimethylamine N-oxide (TMAO), a compound derived from byproducts of intestinal bacteria, has been shown to accelerate atherosclerosis in rodents. To date, there are conflicting data regarding the association of serum TMAO with cardiovascular outcomes in patients with ESKD, a population exhibiting both high serum TMAO and excessive atherosclerosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured baseline serum TMAO concentrations in a subset of participants (n=1243) from the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial and conducted post hoc analyses evaluating the association between baseline serum TMAO and cardiovascular outcomes. RESULTS: We observed a wide distribution of serum TMAO in our cohort, with approximately 80% of participants exhibiting TMAO concentrations ≥56 µM and a maximum TMAO concentration of 1103.1 µM. We found no association between TMAO and our primary outcome, a composite of cardiovascular mortality, myocardial infarction, peripheral vascular event, stroke, and hospitalization for unstable angina. Moreover, in unadjusted and adjusted analyses, we observed no relation between TMAO and all-cause mortality, the independent components of our composite outcome, or the original EVOLVE primary outcome. Although we did observe higher TMAO concentrations in white participants, further subgroup analyses did not confirm the previously identified interaction between TMAO and race observed in a prior study in patients receiving dialysis. CONCLUSIONS: We found no evidence linking TMAO to adverse clinical outcomes in patients receiving maintenance hemodialysis with moderate to severe secondary hyperparathyroidism.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Stubbs JR, Stedman MR, Liu S, et al. Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2019. PMID: 30665924. doi:10.2215/CJN.06190518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。